Valuation: PREDILIFE

Market Cap 3.75M 4.27M 3.49M 3.2M 6.01M 411M 6.1M 41.4M 16.17M 202M 16.02M 15.68M 699M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 8.53M 9.71M 7.93M 7.28M 13.67M 935M 13.88M 94.16M 36.79M 460M 36.44M 35.66M 1.59B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 week-26.92%
Current month-58.70%
1 month-60.58%
3 months-69.35%
6 months-71.47%
Current year-68.44%
1 week 0.95
Extreme 0.95
1.29
1 month 0.95
Extreme 0.95
2.57
Current year 0.95
Extreme 0.95
4
1 year 0.95
Extreme 0.95
4
3 years 0.95
Extreme 0.95
24
5 years 0.95
Extreme 0.95
24
10 years 0.95
Extreme 0.95
24
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
7/27/23 Buy

Chief Executive Officer

1,200 0.0328%
3/23/22 Sell

Chief Executive Officer

3,000 0.0820%
3/9/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-26.92%-72.46%-82.57% 4.27M
-2.19%-4.26%+124.20%+98.42% 4.52B
-0.18%-2.84%+107.16%+183.69% 3.56B
-2.73%-0.20%+59.42%-29.62% 2.23B
-0.90%+1.56%-30.49%-37.69% 2.07B
-1.25%-6.52%+190.38%+237.33% 1.92B
-4.11%-6.63%+151.30%-42.22% 997M
-0.54%-4.03%-9.12%+32.37% 855M
-3.59%-6.57%-42.53%-18.46% 479M
+4.02%-5.71%-0.26% - 457M
Average -1.15%-5.04%+47.76%+37.92% 1.71B
Weighted average by Cap. -1.48%-2.62%+87.76%+83.39%

Financials

2024 2025
Net sales 493K 562K 459K 421K 791K 54.08M 803K 5.45M 2.13M 26.59M 2.11M 2.06M 91.92M 836K 952K 777K 713K 1.34M 91.64M 1.36M 9.23M 3.61M 45.05M 3.57M 3.5M 156M
Net income -4.26M -4.86M -3.97M -3.64M -6.84M -468M -6.94M -47.1M -18.4M -230M -18.23M -17.84M -795M -3.93M -4.48M -3.66M -3.36M -6.31M -431M -6.41M -43.45M -16.98M -212M -16.82M -16.45M -733M
Net Debt 3.54M 4.03M 3.29M 3.02M 5.67M 388M 5.76M 39.08M 15.27M 191M 15.12M 14.8M 659M 4.78M 5.44M 4.44M 4.08M 7.66M 524M 7.78M 52.76M 20.61M 258M 20.42M 19.98M 890M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
26-07-24 €0.9500 0.00% 0
26-07-23 €0.9500 -9.52% 1,836
26-07-22 €1.050 -8.70% 1,317
26-07-21 €1.150 -10.85% 999
26-07-20 €1.290 -0.77% 4,228

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock